Researchers at the University of Cincinnati and Johns Hopkins Medicine have engineered a nanofiber implant that delivers a combination of three drugs directly to glioblastoma tumors. In mouse models, the treatment doubled survival rates compared to controls, a significant advance against one of the deadliest brain cancers.
The implant's nanofibers are embedded with drugs that work in concert, targeting tumors more effectively than any single agent alone. The platform provides both immediate release and sustained, long-lasting doses—potentially overcoming a key limitation of conventional chemotherapy, which often fails to maintain therapeutic concentrations at the tumor site.
According to the study published in a peer-reviewed journal, the triple-drug combination showed superior efficacy versus individual or paired drug regimens. The researchers noted that the approach allowed for precise, localized delivery, minimizing systemic side effects common with intravenous chemotherapy.
The team plans to advance the implant into larger animal models and eventually human clinical trials. If successful, the platform could transform treatment for glioblastoma, which currently has a median survival of about 15 months despite aggressive therapy.
A notable caveat: the findings are limited to mouse models, and human trials remain years away. The complex manufacturing of multi-drug nanofibers also poses scalability challenges that have not yet been addressed.